DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan

Information source: London School of Hygiene and Tropical Medicine
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Malaria, Falciparum

Intervention: Chloroquine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: London School of Hygiene and Tropical Medicine

Official(s) and/or principal investigator(s):
Mark Rowland, PhD, Principal Investigator, Affiliation: LSHTM


The purpose of this study was to provide stronger evidence for extended-dose chloroquine treatment of falciparum-positive Afghan refugees in Northwest Frontier Province (NWFP), Pakistan or justification for discontinuation of the policy.

Clinical Details

Official title: Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: therapeutic and parasitological cure with no recrudescence

Secondary outcome:

parasite clearance time

fever clearance time


Detailed description: To determine whether extended-dose chloroquine provided better cure rates and fewer recrudescences than standard chloroquine treatment among Afghan refugees, 163 falciparum patients from three Afghan refugee camps were recruited into 3-day (CQ 25mg/kg) or 5-day (CQ 40mg/kg) treatment arms and followed for up to 60 days.


Minimum age: 6 Months. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- slide-confirmed infection with P. falciparum only

- initial parasite density of 1000-100,000 asexual parasites/μl

- absence of severe malnutrition

- ability to attend stipulated follow-up visits and easy access to facility

- informed consent provided by patient or parent/guardian

- absence of history of hypersensitivity reactions to CQ

Exclusion Criteria:

- infants under six months old

- pregnancy or lactation

- underlying chronic severe illness

- patients with other febrile illnesses

- parasitaemia outside the range of 1000-100,000 asexual parasites/µl

- severe malaria

Locations and Contacts

Adezai Basic Health Unit, Adezai, Nwfp, Pakistan

Baghicha Basic Health Unit, Baghicha, Nwfp, Pakistan

Kagan Basic Health Unit, Kagan, Nwfp, Pakistan

Additional Information

Starting date: November 1993
Last updated: November 23, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017